AC Immune (ACIU) Non-Current Debt (2017 - 2019)

AC Immune (ACIU) posted quarterly Non-Current Debt of $301440.6 for Q3 2019, up 117968.07% quarter-over-quarter from $255.31 in Q2 2019.

AC Immune (ACIU) Non-Current Debt (2017 - 2019) Analysis & Trends

AC Immune (ACIU) has reported Non-Current Debt for 3 consecutive years, with $301440.6 the latest figure, recorded in Q3 2019.

In Q3 2019, Non-Current Debt changed N/A year-over-year to $301440.6; the TTM figure through Sep 2019 stood at $301440.6 (changed N/A YoY), while the FY2018 annual figure was $186899.3, down 62.67% from the prior year.
Non-Current Debt grew to $301440.6 in Q3 2019 per ACIU's latest filing, from $255.31 in the prior quarter.
Across five years, Non-Current Debt topped out at $500708.2 in Q4 2017 and bottomed at $255.31 in Q2 2019.
Historically, Non-Current Debt has averaged $243043.5 across 3 years, with a median of $225914.1 in 2019.
On a YoY basis, Non-Current Debt climbed as much as 62.67% in 2018 and fell as far as 62.67% in 2018.
AC Immune's Non-Current Debt stood at $500708.2 in 2017, then tumbled by 62.67% to $186899.3 in 2018, then surged by 61.29% to $301440.6 in 2019.
Business Quant data shows ACIU's Non-Current Debt at $301440.6 in Q3 2019, $255.31 in Q2 2019, and $225914.1 in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	AC Immune	253.89 Mn	253.89 Mn	-	-

Download Data